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Abstract  
Introduction: We report the co-occurrence of a SDHD and a SDHB mutation in a family with hereditary paraganglioma 
syndrome.  We compare this finding to simultaneous haploinsufficiency of BRCA1 and BRCA2. 
Presentation of Case: The 28 year old proband presented as an isolated case in the family with a malignant phaeochromocytoma.  
Sequencing and MLPA of SDHD and SDHB were performed.  A SDHD splice site mutation, c.169+5G>A, was identified in the 
proband, his sister and their father.  In addition, a SDHB exon 1 deletion was identified by MLPA in the proband, his sister and 
their mother.  Both mutations have been described previously and considered to be pathogenic. An appropriate screening 
programme was instituted for carrier relatives.   
Conclusions: To our knowledge, this is the first report of two SDH subunit mutations in a single family.  Though there was no 
family history to suggest inherited disorder, the simultaneous testing of both genes was diagnostic.  The family history is 
consistent with suggestions that the penetrance of SDHB/SDHD mutations is lower than initially thought.   
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Introduction 
The genetic predisposition to develop head and neck 
paragangliomas (HNPGL) has been recognised since 
1982 and the association of HNPGL with 
phaeochromocytomas since 1974 [1, 2]. Several genes 
have since been identified that are associated with the 
hereditary paraganglioma/phaeochromocytoma 
syndromes. These include the succinate 
dehydrogenase genes of the complex II respiratory 
chain in the mitochondria, namely SDHA, SDHB, 
SDHD, SDHC and SDHAF2 [3-6]. Other genes 
involved in phaeochromocytoma/paraganglioma 
include NF1, VHL, RET, TMEM127 and MAX [7-10]. 
Familial phaeochromocytoma/paraganglioma 
syndromes caused by succinate dehydrogenase subunit 
mutations are inherited in an autosomal dominant 
manner, though SDHD mutations usually only cause 
disease if inherited from the father [11, 12]. Patients 
with SDHD or SDHB mutations are at risk of adrenal 
and extra-adrenal phaeochromocytomas and HNPGL 
as well as a smaller risk of additional tumours, for 
example, renal, thyroid and gastrointestinal stromal 
cell tumours. The mean age of diagnosis in patients 
with SDHD mutations is 31 years old and with SDHB 
mutations is 34 years [13].  
The penetrance of tumours in SDHD mutations has 
been estimated at 50% by 31 years and 86% by 50 
years [14]. The site-related penetrance of SDHD 
mutations has been reported as 71% at 60 years for 
head and neck paragangliomas and as 29% at 60 years 
for phaeochromocytomas [13]. 
The penetrance of SDHB mutations was described 
initially as 50% for paragangliomas by 35 years and 
77% by 50 years [14]. Some studies, however, suggest 
that, at least for some mutations, the penetrance may 
be lower than this estimate [13, 15]. The site-related 
penetrance has been estimated at 29% at 60 years for 
head and neck paragangliomas and 52% at 60 years 
for phaeochromocytomas. The risk of renal tumours is 
14% at 70 years with an SDHB mutation [11]. Up to 
30% of patients with an isolated paraganglioma or 
phaeochromocytoma have a germline mutation, and it 
has been suggested that comprehensive mutation 
testing should be considered to identify these patients 
[16, 17]. SDHB mutations are the most commonly 
identified. SDHB mutations convey a higher risk of 
malignant transformation of these tumours [14,18].   
Biochemical and radiological surveillance is 
generally offered to all SDHB /SDHD mutation 
carriers and a recommended screening programme 
includes an annual MRI of the pelvis and abdomen, 3 
yearly MRI screening from the head and neck to the 
base of spine and annual 24-hour urine metadrenaline 
analysis.  
Materials and methods 
The SDHB gene contains 8 exons and SDHD contains 
4 exons. Direct sequencing of the coding exons and 
flanking intronic regions of the exons in both genes 
was performed using standard PCR and sequencing 
reactions (BigDye v3.1;Applied Biosystems Inc., 
Foster city, CA). Sequencing reactions were analyzed 
using an ABI 3730 DNA Analyzer (Applied 
Biosystems Inc.) for SDHB and on an ABI 3170 DNA 
Analyzer (Applied Biosystems Inc.) for SDHD. The 
data was analysed by Mutation Surveyor variant 
analysis software V3.30 (primer sequences on request). 
Nucleotide numbering reflects cDNA numbering with 
+1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence 
(SDHB–NM_003000.2; SDHD–NM_003002.2), 
according to journal guidelines 
(www.hgvs.org/mutnomen). The initiation codon is 
codon 1. 
Screening for germline SDHB, SDHD and SDHC exon 
deletions was performed by MLPA dosage analysis 
using MRC-Holland Kit P226 and SoftGenetics 
GeneMarker analysis software. Further investigation 
of the common SDHB exon 1 deletion was undertaken 
by PCR amplifications from regions either side of the 
deletion (primer sequences on request). This was 
performed to check for any sequence variant which 
may prevent probe hybridisation and cause a false 
copy number result by MLPA.  
Case Presentation and Results 
The proband presented with a metastatic 
 Cilliers D et al. American Journal of Cancer Case Reports. 2013, 1:27-33 
 
Ivy Union Publishing | http: //www.ivyunion.org March 25 2013 | Volume 1 | Issue 1  
Page 3 of 7 
paraganglioma at age 28 years. He reported a one year 
history of increasing lower back pain and sciatica of 
the left leg with altered sensation in the anterior aspect 
of his upper thigh, together with significant weight 
loss and night sweats. He did not complain of 
headaches, palpitations, or exertional symptoms.  
When this was investigated, a CT scan and MRI 
scan identified a large adrenal mass with disease 
extending retroperitoneally around the lower 
thoracic/lumbar vertebrae at T12/L1, encroaching onto 
the spinal cord and cauda equina. The 
para-oesophageal nodes were also enlarged and the 
presence of lung deposits was detected. There were 
multiple bone metastases throughout the skeleton seen 
on an MIGB scan, including uptake in the skull, right 
shoulder, spine, lower ribs, left ileum, and left 
thoracolumbar region, in keeping with the 
paravertebral mass. Biopsy from one of the bone 
lesions confirmed paraganglioma.  
Plasma catecholamines and metanephrines and 
24-hour urine catecholamines were normal, 
confirming non-secretory disease. Plasma calcium and 
calcitonin levels were also normal making Multiple 
Endocrine Neoplasia type 2 (MEN2) unlikely.  
In view of the widespread metastases and poor 
prognosis he was given initial palliative radiotherapy 
to the spine and MIBG radio-isotope therapy. The 
avidity of the uptake in the latter treatment was poor 
and it was therefore discontinued after 1 cycle. He was 
subsequently given palliative chemotherapy with six 
cycles of cyclophosphamide, vincristine, and 
dacarbazine (CVD) with additional bisphosphonate 
therapy.  
He presented as an isolated case in the family, as 
can be seen in the pedigree (Figure 1). After the 
identification of germline SDHB and SDHD mutations 
in the proband (see later), his first degree relatives 
were offered presymptomatic genetic testing.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Pedigree of the family with double heterozygosity of a SDHD and a SDHB mutation. 
 
The proband’s sister was 33 years old when she 
presented for predictive testing. Although she worked 
in the nuclear industry, she has not been exposed to 
ionising radiation and has no recorded radiation dose 
in the workplace. On examination, she had several 
neck masses which later proved to be enlarged lymph 
nodes due to infection caused by eczema. Her MRI 
scan from the base of skull to pelvis and urine 
metadrenaline screening showed no abnormalities. 
Their father was well at 58 years old and had no 
clinic signs of hereditary paraganglioma syndrome. 
His MRI scan from base of skull to pelvis and urine 
metadrenaline screening demonstrated no 
abnormalities. The paternal grandfather had died at 51 
years of an illness unrelated to hereditary 
paraganglioma syndrome and the paternal 
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grandmother was alive at 85 years with no signs of 
hereditary paraganglioma syndrome.  
The proband’s mother (aged 60 years) had been 
diagnosed with unilateral breast cancer at 53 years and 
had recovered following surgery. Her examination was 
normal and her MRI scan from the base of skull to 
pelvis and urine metadrenaline screening were normal. 
Recently she presented with symptoms of gastritis 
which did not improve with medication. A CT scan of 
the thorax identified a mass surrounding the lower 
oesophagus. Histological examination confirmed 
metastatic breast cancer. The maternal grandparents 
were deceased, the grandfather from lung cancer. A 
half-sister had no signs of hereditary paraganglioma 
syndrome.  
Molecular genetic studies in the proband identified 
a SDHD and a SDHB mutation. A heterozygous SDHD 
splice site mutation, c.169+5G>A, was identified in 
exon 2. A heterozygous deletion of exon 1 of SDHB 
was also identified in the proband.  
Predictive testing was offered to the family. Both 
mutations were identified in the proband’s sister. The 
proband’s mother carried the exon 1 deletion in SDHB 
and the proband’s father carried the SDHD mutation, 
c.169+5G>A in exon 2. The paternal grandmother was 
tested for the familial SDHD mutation and she did not 
carry the mutation.  
Discussion 
To our knowledge, this is the first report of a family in 
which two likely pathogenic mutations in genes 
associated with hereditary paraganglioma syndrome 
have been identified.  
The SDHD c.169+5G>A splice site mutation has 
been previously described as a likely pathogenic 
mutation in a single report. Thus Timmers et al., 
described an isolated case of a 43 year old male 
presenting with a bilateral tympanojugular and carotid 
tumour with this mutation [19]. cDNA analysis 
suggested that this mutation resulted in the skipping of 
exon 2. Skipping of exon 2 in SDHD would delete a 
large part of the first transmembrane helix, the loop 
joining the first and 2nd transmembrane helix and the 
N-terminal portion of the 2nd transmembrane helix, 
with the likelihood of this reducing the ability to bind 
with the other proteins in the SDH complex [20]. This 
mutation is therefore likely to be pathogenic. A similar 
SDHD mutation, c.169+1G>T, has also been described 
as likely to be pathogenic in two unrelated cases [21].   
Exon 1 SDHB mutations have been reported on 
several occasions and are thought to be pathogenic. A 
SDHB deletion that involved exon 1 has been reported 
as an Iberian founder mutation, having being mostly 
been identified in Spanish families. The penetrance of 
this mutation was estimated in a large family and was 
found to be lower than previously reported for SDHB 
mutations at 35% at 40 years [22, 23]. Exon 1 
deletions of varying sizes have been described and all 
have been considered to be pathogenic, although the 
exact size of our patient’s deletion has not been 
determined. The presence of deletions may be related 
to abdominal presentation and a younger age at onset 
[13, 23].  
The implications for clinical management of this 
family were complex. The proband’s sister is at risk of 
head and neck as well as extra-adrenal tumours, but 
the risk cannot be accurately quantified with current 
knowledge.  
Following the detection of the SDHD mutation in 
the proband’s father, the tumour risk was unclear 
initially, but further testing demonstrated that he had 
not inherited the mutation from his mother and so it is 
most likely that it was paternally inherited (de novo 
SDHD mutations appear to be very rare) and hence he 
is predicted to be at risk of developing HNPGL and/or 
phaeochromocytoma. The mother of the proband was 
asymptomatic at presentation. She previously had 
breast cancer and recently developed metastatic 
disease. SDHB mutations are not associated with an 
increased risk of breast cancer and not known to 
increase the risk of metastatic disease.  
We suggested a similar screening programme for all 
of the family members, including the sister with two 
mutations. The reason for this was because the 
screening programme is designed specifically to 
identify the tumours caused by SDHB mutations at an 
early stage. These tumours are most likely to undergo 
malignant transformation and require regular 
monitoring. The screening programme would also 
identify the non-secretory head and neck tumours if 
they should occur, although these are more 
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slow-growing and less likely to undergo malignant 
transformation.  
Simultaneous haploinsufficiency has been reported 
previously in cancer genes, most notably in breast 
cancer. Double heterozygosity in BRCA1 and BRCA2 
genes has been reported, particularly in the Ashkenazi 
Jewish population. Double heterozygosity is rare and 
estimated at 2.2% of all gene carriers and in 0.3% of 
all breast cancer cases in this population group. The 
phenotype in these patients suggests an earlier age at 
diagnosis of the associated cancers, but there was no 
increase in the rate of developing cancer. No patients 
have been identified with two mutations in the same 
gene as this is thought to be incompatible with life [24, 
25]. 
Conclusion 
As more genes are shown to be associated with 
hereditary paraganglioma syndrome, in future more 
cases may be identified with a mutation in more than 
one gene, and the accompanying tumour risks for 
these patients may become more apparent.  
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